India to Get Its First Indigenous H5N1 Bird Flu Vaccine for Chickens on November 20

Union Minister of Agriculture and Farmers Welfare, Shivraj Singh Chouhan, will dedicate India’s first indigenous inactivated H5N1 (Clade 2.3.2.1a) vaccine against Highly Pathogenic Avian Influenza (HPAI) in chickens to the nation on 20 November 2026 at the ICAR-NIHSAD, Bhopal.

India will get its first indigenous vaccine against the H5N1 strain of Highly Pathogenic Avian Influenza (HPAI), commonly known as bird flu, on November 20, 2026. Union Agriculture and Farmers Welfare Minister Shivraj Singh Chouhan will dedicate the vaccine to the nation at the ICAR-National Institute of High Security Animal Diseases (ICAR-NIHSAD) in Bhopal.

Developed indigenously by ICAR-NIHSAD, the inactivated vaccine targets the H5N1 virus belonging to Clade 2.3.2.1a. It is the first vaccine developed in India specifically against this clade of the H5N1 virus for chickens.

The development is expected to strengthen India's preparedness against bird flu outbreaks, which pose a significant threat to the poultry industry, farmers' livelihoods and public health.

Highly Pathogenic Avian Influenza is a severe viral disease that can cause mortality of nearly 100 per cent among infected poultry. Outbreaks often lead to large-scale culling of birds and restrictions on poultry trade, resulting in substantial economic losses for farmers and the industry.

Since the first detection of bird flu in India in 2006, the country has reported more than 500 combined outbreaks involving the H5N1 and H5N8 subtypes.

According to the press release, a major bird flu outbreak could reduce India's GDP growth by up to 1.5 per cent, while more than 20 per cent of the country's poultry population could be at risk if the disease spreads unchecked. The 2006 outbreak alone caused estimated direct and indirect losses of Rs. 2,200-3,000 crore. An outbreak in Manipur also resulted in losses equivalent to 0.5 per cent of the state's GDP.

Clade 2.3.2.1a Poses Growing Threat

Studies have identified H5N1 Clade 2.3.2.1a as the strain responsible for most bird flu outbreaks in chickens. In recent years, infections caused by this strain have also been detected in various animal species, including mammals, as well as in three human cases.

This has increased the importance of controlling the virus in poultry to prevent its spread to other animals and humans. The World Health Organization (WHO) has reported 1,003 human cases of H5N1 avian influenza, including 479 deaths, across 25 countries, including India, since 2003.

Until now, no specific commercial vaccine has been available against the H5N1 virus of Clade 2.3.2.1a. The indigenous vaccine developed by ICAR-NIHSAD is intended to fill this gap by providing protection against the Clade 2.3.2.1a H5N1 strains circulating in India.

The development marks an important step towards strengthening domestic capabilities in animal disease prevention and reducing India's dependence on externally developed vaccines for emerging animal health threats.